New hope for chinese patients with severe transplant complication: ruxolitinib trial launches
NCT ID NCT06462469
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests the drug ruxolitinib in 36 Chinese adults and teens (12+) who have severe graft-versus-host disease after a stem cell transplant and did not improve with steroids. Participants take ruxolitinib pills daily for up to 56 days. The main goal is to see how many patients have a complete or partial response by day 28.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
ruxolitinib (oral drug)
What this could lead to
If successful, this could provide a treatment option for Chinese patients with severe graft-versus-host disease that does not respond to steroids.
What could go wrong
This is a small, single-arm Phase 4 study with no placebo group, so results may be less reliable. The drug may not work for all patients and could have side effects like infections or blood cell changes.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for STEROID-REFRACTORY ACUTE GRAFT-VERSUS-HOST DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Locations
-
Novartis Investigative Site
RECRUITINGGuangzhou, Guangdong, 510000, China
-
Novartis Investigative Site
RECRUITINGGuangzhou, Guangdong, 510515, China
-
Novartis Investigative Site
RECRUITINGZhengzhou, Henan, 450003, China
-
Novartis Investigative Site
RECRUITINGWuhan, Hubei, 430030, China
-
Novartis Investigative Site
RECRUITINGChangchun, Jilin, 130021, China
-
Novartis Investigative Site
RECRUITINGXian, Shanxi, 710061, China
-
Novartis Investigative Site
RECRUITINGChengdu, Sichuan, 610072, China
-
Novartis Investigative Site
RECRUITINGHangzhou, Zhejiang, 310003, China
-
Novartis Investigative Site
RECRUITINGBeijing, 100028, China
-
Novartis Investigative Site
RECRUITINGBeijing, 100034, China
-
Novartis Investigative Site
RECRUITINGBeijing, 100039, China
-
Novartis Investigative Site
RECRUITINGBeijing, 100070, China
-
Novartis Investigative Site
RECRUITINGDalian, 116000, China
-
Novartis Investigative Site
RECRUITINGFuzhou, 350001, China
-
Novartis Investigative Site
RECRUITINGShanghai, 200025, China
-
Novartis Investigative Site
RECRUITINGTaian, 271099, China
-
Novartis Investigative Site
RECRUITINGTianjin, 300020, China